

123 - Summary of NICE guidelines for the treatment of GAD, panic disorder and OCD

Depression and anxiety disorders CHAPTER 3 References

1. Nash JR, et al. Pharmacotherapy of anxiety. *HandbExp Pharmacol* 2005; (169):469–501.
2. Munkholm K, et al. Minor tranquillizers for short-term treatment of newly onset symptoms of anxiety and distress: a systematic review with network meta-analysis of randomized trials. *Eur Arch Psychiatry Clin Neurosci* 2024; 274:475–486.
3. Benitez CI, et al. Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study. *Am J Geriatr Psychiatry* 2008; 16:5–13.
4. Demyttenaere K, et al. Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD). *J Affect Disord* 2008; 110:84–93.
5. Hirschtritt ME, et al. Balancing the risks and benefits of benzodiazepines. *JAMA* 2021; 325:347–348.
6. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management. Clinical guideline [CG113]. 2011 (last updated June 2020, reviewed May 2024, last checked November 2024); <https://www.nice.org.uk/guidance/cg113>.
7. Davidson JR. Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. *J Clin Psychiatry* 2004; 65 Suppl 5:29–33.
8. Scott A, et al. Antidepressant drugs in the treatment of anxiety disorders. *Adv Psychiatr Treat* 2001; 7:275–282.
9. Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. *J Clin Psychiatry* 2004; 65:1696–1707.

10. Davidson JR, et al. A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD). *J Psychopharmacol* 2010; 24:3–26.
11. Baldwin DS, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. *J Psychopharmacol* 2014; 28:403–439.
12. Baldwin D, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. *BMJ* 2011; 342:d1199.
13. Snee A, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. *Lancet* 2019; 393:768–777.
14. Kong W, et al. Comparative remission rates and tolerability of drugs for generalised anxiety disorder: a systematic review and network meta-analysis of double-blind randomized controlled trials. *Front Pharmacol* 2020; 11:580858.
15. Caillard V, et al. Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study. French University Antidepressant Group. *Acta Psychiatr Scand* 1999; 99:51–58.
16. Wade AG, et al. The effect of citalopram in panic disorder. *Br J Psychiatry* 1997; 170:549–553.
17. Lønborg PD, et al. Sertraline in the treatment of panic disorder: a multi-site, double-blind, placebo-controlled, fixed-dose investigation. *Br J Psychiatry* 1998; 173:54–60.
18. Pollack MH, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. *J Psychopharmacol* 2003; 17:276–282. Drug Comments Levetiracetam 300–3000mg/day in divided doses¹⁵⁶ Moclobemide 600mg/day in divided doses Initiate at 300mg/day in divided doses. Has a UK licence for social phobia. Recommended by NICE.¹⁴⁸ Phenelzine 15–90mg/day¹⁵⁷ Avoidance of tyramine-rich food important. Recommended by NICE.¹⁴⁸ Pregabalin 150–600mg/day¹⁵³ 600mg/day superior to placebo¹⁵³ Experimental Ketamine 0.5mg/kg IV One good RCT,¹⁵⁸ one post hoc analysis¹⁵⁹ Topiramate 25–400mg/day¹⁶⁰ Small open-label study of 23 patients suggests efficacy but poorly tolerated Valproate 500–2500mg/day¹⁶¹ Small open-label study of 17 patients suggests efficacy

Revision #1

Created 2026-01-04 20:15:08 UTC by Omar Ayman

Updated 2026-01-04 20:15:08 UTC by Omar Ayman